Leland Stanford Junior University

Johns Hopkins University

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Washington University

Indiana University

Terrapin Technologies, Inc.

The United States of America as Represented by Nih Division of Extramural Inventions and Technology Resources (Deitr)

Daria D Mochly-Rosen

Che-Hong Chen

Wenjin Yang

Nir Qvit

Dorit Ron

Leon E Chen

Joan J Kendig

Sarah M Sweitzer

Xin Qi

Rachel Bright

Kam W Leong

Corinne Bright

Xiaohu Ouyang

Eric Gross

Koichi K Inagaki

Marie-Helene Disatnik Dziesietnik

Eric Churchill

Lawrence M Kauvar

David C Yeomans

Gerald W Dorn, Ii

Eugene W Napolitano

Thomas D Hurley

Vanessa Zambelli

Carl Hurt

Quynh-Thu Le

Relly Brandman

Stacy Lynn McAllister

Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.

Methods and compositions for treating endometriosis and endometriosis associated symptoms

Methods of modulating the interaction between calcineurin and a calcineurin-binding protein partner are provided. Aspects of the methods include contacting a cell with a peptidic agent that modulates the interaction between calcineurin and a TRPV channel. Also provided are pharmaceutical compositions that comprise a peptidic agent that selectively modulates the interaction between calcineurin and a calcineurin-binding protein partner. Also provided are methods of treating a condition in a subject by selectively modulating the interaction between calcineurin and a calcineurin-binding TRPV channel. Also provided are screening methods to identify candidate agents that modulate calcineurin protein-protein interactions.

Peptide modulators of specific calcineurin protein-protein interactions

The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on binding of dynamin-1-related protein (Drp1) GTPase activity, Drp1 to mitochondrial fission 1 protein (Fis1), reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.

Inhibitors of mitochondrial fission and methods of use thereof

Mitofusin modulatory peptides are described which may function as activators or inhibitors of mitochondrial fusion. The sequences and compositions comprising the sequences are useful for treating diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2) and mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides for use in screening assays are also described.

Peptide regulators of mitochondrial fusion and methods of use

The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an individual undergoing radiotherapy for head and neck cancer.

Compositions and methods for increasing proliferation of adult salivary stem cells

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

A peptide composition is provided which specifically inhibits the ability of &#x3b4;-protein kinase C (&#x3b4;PKC) to phosphorylate pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion.

Compositions and methods for specific regulation of pyruvate dehydrogenase kinase

A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue.

Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds. 

Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof

Methods and compositions are provided for treating pain in an individual. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. These methods find many uses, for example in treating and preventing nociceptive pain, inflammatory pain, and neuropathic pain.

Methods and compositions for treating pain

The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.

Modulators of aldehyde dehydrogenase and methods of use thereof

PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.

Peptide inhibitors of protein kinase C

The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.

Growing community of inventors

Melo Park, CA, United States of America

Daria D Mochly-Rosen